Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

53.15 -1.06 (-1.96%)

Streaming Delayed Price Updated: 10:40 AM EDT, Sep 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

New Hope for Nerve Damage Patients as AstraZeneca/Ionis' Eplontersen Receives FDA Nod for Hereditary Amyloidosis Treatment ↗

December 22, 2023

Friday, FDA approved AstraZeneca

Via Benzinga

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Based on good technical signals, IONIS PHARMACEUTICALS INC is potentially setting up for a breakout. ↗

December 19, 2023

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

Where Ionis Pharmaceuticals Stands With Analysts ↗

November 17, 2023

Via Benzinga

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

November 16, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

October 23, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

September 27, 2023

Via Benzinga

Technical Insights for IONIS PHARMACEUTICALS INC (NASDAQ:IONS): Is a Breakout Imminent? ↗

November 10, 2023

Technical Setup: IONIS PHARMACEUTICALS INC Appears Poised for a Breakout.

Via Chartmill

Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat ↗

November 02, 2023

Via Benzinga

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗

October 17, 2023

Via Benzinga

Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day

October 02, 2023

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 ↗

September 29, 2023

Via Benzinga

Why Ionis Pharmaceuticals Stock Popped Today ↗

September 26, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading higher Tuesday after the company announced the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant...

Via Benzinga

Ionis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging Action ↗

September 26, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a hereditary disease that prevents...

Via Benzinga

Ionis Climbs On Late-Stage Trial Results For Body Fat Disorder ↗

September 26, 2023

IONS stock rose after Ionis said Olezarsen succeeded in reducing abnormally high levels of body fat inpatients with a rare genetic disorder.

Via Investor's Business Daily

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) Highlighted for Surprising Price Action

September 26, 2023

Via Investor Brand Network

The 7 Most Hated Stocks by Institutional Traders ↗

September 20, 2023

Discover the surprising stocks institutional traders are selling, and find out what their moves could mean for your portfolio's future.

Via InvestorPlace

Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope ↗

September 07, 2023

Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension,

Via Benzinga

Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports ↗

August 07, 2023

Via Benzinga

Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook ↗

July 31, 2023

Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

Apple To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 31, 2023

Keybanc cut the price target for Baxter International Inc. (NYSE: BAX) from $53 to $51. Keybanc analyst Matthew Mishan maintained an Overweight rating. Baxter International shares rose 1.2% to $47.58...

Via Benzinga

BridgeBio Launches 64% Higher, Pulling Alnylam And Ionis With It, On A 'Best-Case' In Heart Disease ↗

July 17, 2023

The companies are working on treatments for a leading cause of heart failure.

Via Investor's Business Daily

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

June 30, 2023

From Biogen Inc.

Via GlobeNewswire

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million ↗

June 15, 2023

Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.

Via Investor's Business Daily

Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst ↗

June 12, 2023

Sunday, Intellia Therapeutics Inc (NASDAQ: NTLA) announced updated interim results from the Phase 1 portion of the ongoing

Via Benzinga

Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway' ↗

June 07, 2023

Piper Sandler assumed coverage of Ionis Pharmaceuticals Inc (NASDAQ: IONS) with an Overweight rating and a

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.